MedTrace Logo

A Study of Silent Alarm Delivery Versus Standard Audible Alarm Delivery in Intensive Care and High Dependency Units

NCT07364097 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 896

Last updated 2026-04-21

No results posted yet for this study

Summary

The goal of the trial is to learn if a strategy to eliminate audible alarm noise in intensive care and high dependency units can reduce overall noise levels, patient delirium, staff alarm fatigue, and staff burnout. Researchers will implement a silent alarm strategy in specific care units for four weeks and compare this to a separate 4 weeks where a silent strategy is not implemented. Noise, burnout, delirium levels, and staff alarm response times will be compared between the silent and non-silent units.

Conditions

  • Delirium in the Intensive Care Unit
  • Burnout, Healthcare Workers
  • Noise in the ICU
  • Alarm Fatigue
  • Alarm Fatigue in Intensive Care Unit Nurses
  • Alarms
  • Nursing Workload

Interventions

OTHER

Silent alarm strategy

The intervention consists of the implementation of a silent alarm system in the clinical environment. The silent alarm system consists of a self-locating interface device, which is interposed between an alarm-generating device and its audio output. This device contains communication, locating, motion, logic, and relay chips, which enable the interface device to identify its location and staff responsible for that location, as well as to detect audio output from the alarm-generating device, and to control the audible state of that output. The Interface device can communicate with separate bone conduction headsets worn by staff, which contain sensors that confirm staff presence at the headset, and buttons for response to an alarm announcement. The interface device then delivers alarms silently to those staff specifically responsible for its location when a responsible staff member can be identified, confirmed to be present, and accepts responsibility for the alarm through button action.

Sponsors & Collaborators

  • MindWave Medical Inc

    lead INDUSTRY

Principal Investigators

  • Daniel F Niendorff, MD · MindWave Medical

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-02-03
Primary Completion
2026-04-18
Completion
2026-04-18

Countries

  • India

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07364097 on ClinicalTrials.gov